Skip to content
Research Article Open access CC BY 4.0

A Review on Intranasal Covid Vaccines for SARS-CoV-2

R. Santosh Kumar, Pranathi Karanam

Asian Journal of Medicine and Health · pp. 74–86 · Published 10 Jun 2022

10.9734/ajmah/2022/v20i930492

Abstract

As the nasal mucosa is generally the first site of infection, intranasal vaccinations have a distinct advantage over conventional COVID-19 vaccines. According to preclinical and clinical investigations, intranasal vaccination results in significant neutralizing antibody production and mucosal IgA and T cell responses, which prevent SARS-CoV-2 infection in both the upper and lower respiratory tracts. The nasal formulations are non-invasive and have a lot of patient appeals. Intranasal vaccinations allow for self-administration and may be made to persist at room temperature, reducing transportation and storage logistics. We give an overview of nasal vaccinations in this review, with an emphasis on formulation development and ongoing preclinical studies and clinical investigations for SARS-CoV-2 intranasal vaccine preparations.

COVID-19 SARS-CoV-2 nasal vaccine nasal spray antigen-presenting cells (APCs) dendritic cells NALT- nasopharynx-associated lymphoid tissue MALT- mucosa-associated lymphoid tissue BALT- bronchus-associated lymphoid tissue

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.